



GENENTECH, THE ORIGINAL BIOTECH COMPANY

[GENetic ENgineering TECHnology]

For five decades, Genentech has been fueled by a passion for science, driving us to explore uncharted territory and deliver groundbreaking discoveries that have fundamentally changed patients' lives and reduced the burden of complex health challenges on society. As **the original biotech company**, we honor our 50-year legacy by applying the same innovative spirit—the one that creates life-changing therapies — to improve healthcare access and outcomes, ensuring our scientific breakthroughs have a real and positive impact on people's lives.

We are now leading the next revolution in human health, ensuring we remain at the forefront of scientific progress for the next 50 years. Today, we are pioneering the integration of AI and data science into every facet of drug discovery and patient care. This new technological frontier will accelerate our ability to solve the most complex, urgent health challenges in the world.

FOUNDED: April 7, 1976

HEADQUARTERS:
South San Francisco, California

CEO: Ashley Magargee

EMPLOYEES: ~12,100 (U.S.)

PARENT COMPANY: Roche Group

GENENTECH AND ROCHE LEADING THE WAY IN INNOVATION

~\$15 billion invested globally in R&D each year, representing one of the largest R&D budgets in the industry

66 investigational medicines in clinical development, representing one of the largest pipelines in the industry

640 active clinical trials worldwide, with more than 250 active clinical trials in the U.S.

39 million patients worldwide treated with one of our medicines in 2025

\$50 billion commitment in American manufacturing and infrastructure

5 Therapeutic areas: Oncology/Hematology, Neurology, Immunology, Ophthalmology, and CVRM (cardiovascular, renal, and metabolism)

40+ medicines on the market to treat people living with serious diseases

27 new medicines launched over the last sixteen years

43 FDA Breakthrough Therapy Designations granted since 2013 – among the most in the industry

28 manufacturing, distribution, and R&D facilities worldwide, including 7 sites in the U.S. across 5 states

HISTORY OF FIRSTS

1st to commercialize recombinant DNA technology, creating the global biotechnology industry

1st monoclonal antibody approved in the U.S. for cancer (non-Hodgkin's lymphoma)

1st HER2-targeted therapy for metastatic breast cancer, and the first therapeutic antibody launched with a required companion diagnostic to realize the potential of precision medicine

1st first B-cell depleter approved for relapsing and primary progressive forms of multiple sclerosis

ACCESS TO OUR MEDICINES

Over the past **30** years, Genentech has helped **4 million** people through patient assistance programs.

- **320K** people with access issues were helped by Genentech Access Solutions in 2025
- **213K** eligible patients assisted through Genentech Commercial Co-pay Assistance Programs in 2025

Over the past **40** years, the Genentech Patient Foundation has helped more than **900K** patients.

- **75K** eligible patients were provided free medicine by the Genentech Patient Foundation in 2025